Download the Free Prime PubMed App to your smartphone or tablet.
Available for iPhone or iPad:
Also Available:Unbound MEDLINE
Available for Mac and Windows Desktops and laptops:
- Impact of Sex on Comparative Outcomes of Bivalirudin versus Unfractionated Heparin in Patients with Acute Coronary Syndromes Undergoing Invasive Management A pre-specified analysis of the MATRIX trial. [Journal Article]
- EEuroIntervention 2018 May 15
- CONCLUSIONS: In ACS patients, the rates of MACE and NACE were not significantly lower with bivalirudin than with UFH in both sexes.The rate of the composite of urgent TVR,definite ST,or NACE was not significantly lower with a post-PCI bivalirudin infusion than with no post-PCI infusion in both sexes.
- FREE Publisher Full Text
- Radial hemostasis is facilitated with a potassium ferrate hemostatic patch: the Statseal with TR band assessment trial (STAT). [Journal Article]
- EEuroIntervention 2018 May 15
- CONCLUSIONS: The PFHP hemostatic patch facilitated early deflation of the TRB with a nonsignificant increase in forearm hematomas. Use of the PFHP may improve patient throughput and allow for earlier discharge following transradial procedures.
- FREE Publisher Full Text
- Bivalirudin versus heparin in primary PCI: clinical outcomes and cost analysis. [Journal Article]
- OHOpen Heart 2018; 5(1):e000767
- CONCLUSIONS: We did not find clinically relevant changes in patient outcomes, including bleeding complications with reintroduction of heparin in our PPCI protocol. However, the use of heparin was associated with a major reduction in treatment costs.
- PMC Free PDF
- Antithrombotic drugs in cardiovascular medicine: a year in review. [Journal Article]
- COCurr Opin Cardiol 2018 Apr 27
- CONCLUSIONS: In this review, we discuss the most recent clinical trials investigating antithrombotic drugs for cardiovascular diseases published in 2017.
- Publisher Full Text
- Efficacy and safety of bivalirudin for percutaneous coronary intervention in acute coronary syndromes: a meta-analysis of randomized-controlled trials. [Journal Article]
- CRClin Res Cardiol 2018 Apr 13
- CONCLUSIONS: Compared with heparin, bivalirudin was associated with a similar incidence of ischemic events following PCI for ACS. An association of bivalirudin with decreased bleeding was not seen with balanced use of GPI.
- Publisher Full Text
- Bivalirudin bewilderment. [Journal Article]
- KPKardiol Pol 2018; 76(4):711-712
- FREE Publisher Full Text
- Editorial: Why should we use bivalirudin today? [Editorial]
- JIJ Interv Cardiol 2018; 31(2):185-187
- Publisher Full Text
- Comparison of two pediatric cases requiring the use of bivalirudin during cardiopulmonary bypass. [Journal Article]
- PPerfusion 2018 Apr 01; :267659118767374
- CONCLUSIONS: The literature strongly supports a specific infusion rate1-7 (2.5 mg/kg/h) for bivalirudin anticoagulation during extracorporeal circulation. Clinicians must consider the loss of clotting factors and the administration of blood products while adjusting the bivalirudin infusion during bypass. We have now elected to maintain an infusion rate of ≥0.5 mg/kg/h for bivalirudin anticoagulation at our center, based on institutional experience, though consideration for a higher infusion rate for an added margin of safety should be considered. It is imperative to have a well-developed protocol for the management of these cardiopulmonary bypass patients and we offer our one-page timeline of events to help guide other pediatric centers looking to use bivalirudin anticoagulation.
- Publisher Full Text
- Early stent thrombosis: Nearly gone, but never forgotten. [Editorial]
- CCCatheter Cardiovasc Interv 2018 Apr 01; 91(5):849-850
- Early stent thrombosis occurs in ∼1% of patients treated with primary PCI and increases shock, stroke, and mortality. Early stent thrombosis was associated with small stent diameter, failure to use g...
- Publisher Full Text
- Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis. [Journal Article]
- ATArterioscler Thromb Vasc Biol 2018; 38(6):1368-1380
- CONCLUSIONS: These data suggest that targeting the MMP1-PAR1 system may be effective in tamping down chronic inflammatory signaling in plaques and halting the progression of atherosclerosis.
- Publisher Full Text